
Claims

1. A crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide:



characterized by:

- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 20.0°, and 23.5°; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.7°, 15.7°, and 22.0°; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 4.6°, 16.8°, and 20.1°; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.5°, 16.5°, and 18.2°; wherein said crystalline form is an acetonitrile solvate; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 4.0°, 16.1°, and 21.9°; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 16.9°, 19.3°, and 24.8°; wherein said crystalline form is a dimethylsulfoxide solvate; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 11.3°, 16.4°, and 20.3°; wherein said crystalline form is a ethanol solvate;

wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

2. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to claim 1, characterized by:

- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 7.8°, 9.7°, 15.7°, 19.8° and 22.0°;

wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

3. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 17.8°, 18.6°, 20.0°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

4. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 9.8°, 9.9°, 11.7°, 17.8°, 18.6°, 20.0°, 21.5°, 22.8°, 23.2° and 23.5°; wherein said X-ray powder diffraction diagram is obtained by using combined Cu Kα1 and Kα2 radiation, without Kα2 stripping; and the accuracy of the 2θ values is in the range of 2θ +/- 0.2°.

5. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide or of a solvate of that compound, according to claim 3, which essentially shows the X-ray powder diffraction pattern as depicted in Figure 1.

6. The crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, according to any one of claims 3 to 5, wherein said crystalline form is obtainable by crystallisation of the {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide in an aqueous solution at pH 6.2 to 6.8.

7. A crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, according to any one of claims 1 to 5, for use in the

manufacture of a pharmaceutical composition, wherein said pharmaceutical composition comprises as active ingredient the compound {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and at least one therapeutically inert excipient.

8. A pharmaceutical composition comprising as active ingredient a crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide according to any one of claims 2 to 5, and at least one therapeutically inert excipient.

9. A pharmaceutical composition according to claim 8, which comprises as therapeutically inert excipient microcrystalline cellulose, lactose, hydroxypropylcellulose, croscarmellose sodium and magnesium stearate.